Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Semin Immunol ; 13(5): 291-302, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11502164

RESUMO

Researchers and clinicians have tried for decades to use the mechanisms of immunity for the fight against cancer. Early attempts aimed at the instrumentation of soluble immune mediators such as antibodies or cytotoxic proteins for the therapy of malignancies. Major improvements in understanding the induction and regulation of cellular immunity have now made it possible to generate effector cells in cancer patients which are specific for the neoplastic disease. At the beginning of every cellular immune reaction against cancers tumor antigens have to be presented to T cells in order to activate them and drive them into clonal expansion. This is done by antigen presenting cells, the most powerful of which is the dendritic cell (DC). While DC were hard to isolate initially, they can be generated in large numbers in vitro today and manipulated in multiple ways before given back to a patient to induce tumor immunity. Thus, a great amount of hope lies in the use of DC as inducers of tumor immunity. However, the first clinical studies, which have now been completed with only limited success make clear, that still a lot of open questions remain to be answered. This review tries to give an overview of this rapidly developing field, mentioning the major conceptual approaches and techniques, but also discussing important caveats. The next years will show whether we can improve our understanding of DC biology and the mechanisms of immune induction strongly enough to effectively employ DC for immunotherapy of cancer.


Assuntos
Células Dendríticas/imunologia , Neoplasias/imunologia , Animais , Células Dendríticas/fisiologia , Humanos , Imunidade Celular , Imunoterapia Adotiva/métodos , Neoplasias/metabolismo , Neoplasias/terapia
2.
Acta Anaesthesiol Scand ; 44(7): 858-63, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10939699

RESUMO

BACKGROUND: Pulmonary resection may result in a reduction in arterial oxygen pressure as well as in cardiac output. Since cardiac index, oxygen delivery, and oxygen consumption are considered as important determinants of patients' outcome, we evaluated the effects of dopexamine and volume loading on cardiopulmonary variables in patients undergoing pulmonary resection. METHODS: Forty adult patients undergoing pulmonary resection for lung or bronchial tumors were included in an open placebo-controlled study. The patients were selected according to a randomized sequence to group A (n=20) or group B (n=20). Dopexamine (2 microg x kg(-1) x min(-1)) was started when steady state conditions were achieved after induction of anesthesia in group A. Saline 0.9% was given as control (group B). Hemodynamic monitoring was performed using a pulmonary artery catheter. RESULTS: Dopexamine increased heart rate, cardiac output and oxygen delivery compared with control without increasing oxygen consumption during anesthesia and surgery. Furthermore, dopexamine was found not to alter the course of PaO2/FiO2 values. CONCLUSION: In patients undergoing pulmonary resection, dopexamine can be used perioperatively to increase cardiac index without decreasing the PaO2/FiO2 ratio.


Assuntos
Volume Sanguíneo/fisiologia , Dopamina/análogos & derivados , Hemodinâmica/efeitos dos fármacos , Oxigênio/sangue , Procedimentos Cirúrgicos Pulmonares , Vasodilatadores/farmacologia , Idoso , Neoplasias Brônquicas/cirurgia , Dopamina/farmacologia , Feminino , Humanos , Neoplasias Pulmonares/cirurgia , Masculino , Pessoa de Meia-Idade , Testes de Função Respiratória
3.
Hum Gene Ther ; 9(4): 561-73, 1998 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-9525317

RESUMO

Adenoviral vectors are being developed for oral delivery of therapeutic genes to the intestine. Initial studies in the rat using mucolytics and direct application of adenovirus encoded with the interleukin-1 receptor antagonist gene to the jejunum produced limited gene expression. The goal of this study was to determine the role of integrins in adenovirus-mediated gene delivery to the intestinal epithelium. Integrins are involved in cellular differentiation and tight junction formation and mediate adenoviral internalization. Results from Caco-2 and IEC-18 cells suggest that, as enterocytes differentiate, cell-surface integrin expression decreases. Pretreatment of Caco-2 cells with RGD peptides reduced adenoviral transduction efficiency by 80% in undifferentiated cells and 20% in differentiated cells. Both differentiated and undifferentiated IEC-18 cells showed a 70% drop in transduction when pretreated with the peptide. Infection inhibition studies with monoclonal antibodies further suggest that alpha(v)beta3 and alpha6beta1 integrins play significant roles in adenoviral internalization in the intestine. Expression of integrins in cell culture models of the intestine correlated with in vivo expression in intestinal segments. These results indicate that the ileum is a prime target for efficient adenovirus-mediated gene transfer in the rat. To enhance transduction in differentiated enterocytes (probable targets for oral gene delivery), Caco-2 cells were treated with interleukin-1beta (a cytokine known to increase integrin expression) prior to administration of the virus. Transduction efficiency increased four-fold.


Assuntos
Adenovírus Humanos/genética , Técnicas de Transferência de Genes , Vetores Genéticos/genética , Integrinas/fisiologia , Mucosa Intestinal , Animais , Células CACO-2 , Diferenciação Celular , Linhagem Celular , Impedância Elétrica , Feminino , Humanos , Íleo , Integrinas/análise , Interleucina-1/farmacologia , Mucosa Intestinal/citologia , Jejuno , Oligopeptídeos/farmacologia , Ratos , Ratos Sprague-Dawley , Proteínas Recombinantes de Fusão/análise
4.
Anaesthesist ; 46(9): 771-5, 1997 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-9412257

RESUMO

OBJECTIVE: To study the influence of dopexamine on pulmonary shunt and hypoxic pulmonary vasoconstriction during major thoracic surgery with one-lung ventilation (OLV). DESIGN: Prospective, randomised, placebo-controlled study. SETTING: University hospital. PATIENTS: Twenty adult patients undergoing elective pulmonary resection. ANAESTHESIA: General anaesthesia was performed using propofol, fentanyl, N2O and vecuronium. Volume-controlled ventilation was performed to maintain normocapnia over the whole investigation period. During OLV, the tidal volume was reduced and the respiratory rate was increased to avoid a peak airway pressure exceeding 40 cm H2O. Furthermore the FiO2 was increased to 1.0 and the external PEEP was removed during OLV. INTERVENTIONS: The patients received either dopexamine at 2 micrograms/kg/min (group A, n = 10) or 0.9% saline as control (group B, n = 10) after assessing the baseline values. MEASUREMENT AND RESULTS: The following cardiorespiratory variables were recorded: Heart rate, mean arterial pressure and mean pulmonary arterial pressure. Cardiac output was measured by thermodilution using a continuous cardiac output thermodilution catheter. Arterial and mixed venous blood gas analysis were measured from simultaneously drawn samples. Cardiac index (CI), systemic vascular resistance index, pulmonary vascular resistance index, oxygen delivery index (DO2I), oxygen consumption index and the venous admixture were calculated using standard formula. Furthermore, pressure-flow-curves were constructed to analyse flow independent changes in the pulmonary vascular resistance. Data were recorded at the following times: After induction of anaesthesia in stable haemodynamics during two-lung ventilation (baseline values, T0), intraoperatively during one-lung ventilation (T1) and postoperatively after re-establishing two-lung ventilation (T2). Patients characteristics, data from the preoperative lung function testing and surgical procedures did not differ significantly between the groups. CI increased in the dopexamine group from 2.5 +/- 1.2 1.min-1.m-2 (T0) to 3.6 +/- 0.9 l.min-1.m-2 (T1) and 4.0 +/- 1.3 l.min-1.m-2 (T2). The course of the intrapulmonary right-to-left shunting did not differ between the groups. In the dopexamine-treated group the DO2I increased from 430 +/- 143 ml.min.m-2 (T0) to 652 +/- 255 ml.min.m-2 (T1) and 653 +/- 207 ml.min.m-2 (T2). Regarding the pressure-flow-curves there was no difference during OLV between the two groups indicating no major blocking effect of dopexamine on hypoxic pulmonary vasoconstriction. CONCLUSION: It is concluded that dopexamine can be used to improve haemodynamics and oxygen delivery during thoracic surgery without increasing venous admixture during one-lung ventilation.


Assuntos
Agonistas de Dopamina/uso terapêutico , Dopamina/análogos & derivados , Circulação Pulmonar/fisiologia , Procedimentos Cirúrgicos Torácicos/métodos , Idoso , Anestesia Geral , Dopamina/uso terapêutico , Método Duplo-Cego , Feminino , Hemodinâmica/efeitos dos fármacos , Hemodinâmica/fisiologia , Humanos , Período Intraoperatório , Masculino , Pessoa de Meia-Idade , Respiração com Pressão Positiva , Estudos Prospectivos , Circulação Pulmonar/efeitos dos fármacos , Respiração Artificial , Testes de Função Respiratória , Volume de Ventilação Pulmonar/efeitos dos fármacos , Volume de Ventilação Pulmonar/fisiologia , Capacidade Vital/efeitos dos fármacos , Capacidade Vital/fisiologia
5.
J Pharm Sci ; 85(10): 1070-6, 1996 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8897273

RESUMO

The diverse secretory and absorptive functions of the intestinal epithelium are conducted by a mixed population of absorptive cells and mucus-producing goblet cells as the major cell types. In order to approach the main characteristics in an in vitro model, a coculture system of absorptive Caco-2 cells and mucus-secreting HT29-MTX cells was developed and the permeability of a range of different drugs was tested. Variable goblet cell frequency can be achieved, preserving a significant barrier to drug transport and maintaining the differentiated features of both cell types. Absorption rates for actively transported drugs are rather underestimated in the cell culture model when compared to in vivo data. However, a good correlation with fraction absorbed in humans was attained separating the range of passively transported drugs into two groups of well-absorbable compounds with Peff > or = 10 x 10(-6) cm/s and drugs that are absorbed 40-70% with Peff = 0.1-1 x 10(-5) cm/s. A permeability of Peff < 0.1 x 10(-5) cm/s is suggested for low absorbable drugs.


Assuntos
Células CACO-2/metabolismo , Células HT29/metabolismo , Mucosa Intestinal/metabolismo , Preparações Farmacêuticas/metabolismo , Animais , Transporte Biológico Ativo , Células CACO-2/ultraestrutura , Cefalexina/metabolismo , Técnicas de Cocultura , Células HT29/ultraestrutura , Humanos , Metildopa/metabolismo , Modelos Biológicos , Muco , Permeabilidade , Propranolol/metabolismo , Ratos
6.
Hum Gene Ther ; 6(12): 1553-60, 1995 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8664380

RESUMO

One of the major obstacles to pulmonary-directed gene therapy using adenoviral vectors is the induction of inflammation. We investigated whether the adenoviral particles that constitute the initial inoculum can serve as an inflammatory stimulus, independent of their ability to express genes that they contain. Viral particles were prepared that are defective in gene expression by (i) isolating particles that have incomplete genomes by selecting those that have buoyant densities on CsCl density gradients lighter than complete viruses; and (ii) cross-linking viral DNA by exposure to ultraviolet light in the presence of 8-methoxypsoralen. The defective particles retained their icosahedral appearance when viewed by electron microscopy but lost their plaque-forming ability on 293 cells. High doses of intact, incomplete, or inactivated viral particles were instilled intratracheally into CBA/J mice, and after 6 days the amount of inflammation was quantified by counting inflammatory cells contained within lung tissue. We found that the inflammatory responses induced by the incomplete or inactivated viral vectors were quantitatively similar to those caused by intact, competent viral vectors. We conclude that high doses of adenoviral vectors that are used for gene therapy can induce pulmonary inflammation, independent of expressing the genes they contain.


Assuntos
Adenoviridae/imunologia , Vírus Defeituosos/imunologia , Vetores Genéticos/imunologia , Pneumonia/etiologia , Adenoviridae/efeitos dos fármacos , Adenoviridae/efeitos da radiação , Adenoviridae/ultraestrutura , Animais , Linhagem Celular , Vírus Defeituosos/ultraestrutura , Terapia Genética , Vetores Genéticos/genética , Humanos , Subpopulações de Linfócitos/imunologia , Masculino , Metoxaleno/farmacologia , Camundongos , Camundongos Endogâmicos CBA , Receptores de Interleucina-1/genética , Raios Ultravioleta , Vírion/imunologia , Vírion/ultraestrutura
7.
Hum Gene Ther ; 6(3): 307-16, 1995 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-7779914

RESUMO

In this report, we present data showing that a recombinant adenoviral vector (Ad.RSVIL-1ra) containing the cDNA for human interleukin-1 receptor antagonist protein (IL-1ra) can genetically modify synoviocytes both in vitro and in vivo. Human synoviocytes infected with Ad.RSVIL-1ra in vitro expressed and secreted high levels of human IL-1ra that were detected by ELISA of tissue culture supernatants. New Zealand White rabbits that received intra-articular injections of Ad.RSVIL-1ra expressed transgenic IL-1ra in synoviocytes, and secretion was detected for at least 4 weeks post-infection. Further, biological activity of the transgenic IL-1ra was demonstrated by its ability to inhibit IL-1-induced prostaglandin E2 (PGE2) synthesis in vitro and IL-1-induced glycosaminoglycan (GAG) degradation in vivo. These data demonstrate that recombinant adenoviral vectors can mediate the intra-articular expression of anti-inflammatory proteins and may be a reasonable method to deliver therapeutically relevant proteins for the regional treatment of synovial inflammation.


Assuntos
Adenoviridae/genética , Vetores Genéticos/química , Vetores Genéticos/genética , Receptores de Interleucina-1/antagonistas & inibidores , Sialoglicoproteínas/genética , Membrana Sinovial/efeitos dos fármacos , Membrana Sinovial/virologia , Animais , Anti-Inflamatórios/farmacologia , Elementos Antissenso (Genética) , Southern Blotting , Linhagem Celular Transformada/virologia , Células Cultivadas/virologia , DNA/análise , DNA/química , DNA Complementar/química , DNA Complementar/genética , Dinoprostona/antagonistas & inibidores , Dinoprostona/biossíntese , Ensaio de Imunoadsorção Enzimática , Humanos , Proteína Antagonista do Receptor de Interleucina 1 , Interleucina-1/farmacologia , Articulação do Joelho , Coelhos , Proteínas Recombinantes/farmacologia , Sialoglicoproteínas/metabolismo , Sialoglicoproteínas/farmacologia , Membrana Sinovial/citologia , Irrigação Terapêutica , Fatores de Tempo , Transdução Genética
8.
Proc Natl Acad Sci U S A ; 90(20): 9480-4, 1993 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-7692448

RESUMO

The most common cause of cystic fibrosis is deletion of Phe-508 (delta F508) from the cystic fibrosis transmembrane conductance regulator (CFTR). Previous studies have suggested that delta F508 CFTR is an unstable protein that retains a pattern of glycosylation specific to the endoplasmic reticulum. This report examines the mechanism responsible for the mislocalization of delta F508 CFTR in a human cystic fibrosis epithelial cell line overexpressing recombinant CFTR by virtue of adenovirus-mediated gene transfer. Immunoelectron microscopy confirmed that wild-type CFTR is delivered to the plasma membrane of these cells and that delta F508 CFTR is retained in the endoplasmic reticulum. Pulse-chase studies showed that newly synthesized CFTR complexes with the chaperone hsp70. The wild-type protein dissociates from hsp70 before its transport to the Golgi, and the protein is subsequently degraded in lysosomes. By contrast, the complex formed between delta F508 CFTR and hsp70 is retained in the endoplasmic reticulum and delta F508 CFTR is rapidly degraded in a pre-Golgi nonlysosomal compartment. Thus, hsp70 discriminates between the normal form of CFTR and the form of the protein that most commonly causes cystic fibrosis (delta F508). These findings clarify the mechanism by which mutation causing delta F508 affects the intracellular trafficking of CFTR and suggest another function for hsp70 in ensuring quality control during the biosynthesis of plasma-membrane proteins.


Assuntos
Proteínas de Choque Térmico/metabolismo , Proteínas de Membrana/metabolismo , Transporte Biológico , Compartimento Celular , Linhagem Celular , Membrana Celular/metabolismo , Chaperoninas , Regulador de Condutância Transmembrana em Fibrose Cística , Retículo Endoplasmático/metabolismo , Técnicas In Vitro , Proteínas de Membrana/genética , Microssomos/metabolismo , Ligação Proteica , Proteínas/metabolismo , Proteínas Recombinantes/metabolismo , Deleção de Sequência , Transfecção
9.
Nucleic Acids Res ; 15(11): 4535-52, 1987 Jun 11.
Artigo em Inglês | MEDLINE | ID: mdl-3453115

RESUMO

Four DNaseI hypersensitive (HS) chromatin regions were found in the uteroglobin locus located at -3.7, -2.4, -0.1 and +4.1 kb with respect to the transcription start site of the gene. The three sites upstream of the gene are only detected in the hormonally stimulated endometrium and disappear after hormone withdrawal, whereas the site at +4.1 is also found in tissues that do not express uteroglobin. In the -2.4 HS region, which is strictly dependent on progesterone treatment, three DNaseI sites are clustered within a 240 bp DNA segment that contains 20 imperfect repeats of an octanucleotide motif. Upstream of the uteroglobin gene there are three regions containing binding sites for the glucocorticoid and the progesterone receptors, located at -3.7, -2.6/-2.7 and -2.4. The -2.4 region contains two binding sites for the hormone receptors flanking the central HS site. In footprinting experiments with naked DNA binding of the receptor also renders this site more susceptible towards digestion with DNaseI. The -2.6/-2.7 region contains three binding sites for the hormone receptors located 140 bp upstream of the HS -2.4. While the -3.7 HS is also located within a receptor binding fragment, there is no binding of the hormone receptors to the promoter region. Thus, interaction of the receptor with DNA sequences far upstream from the promoter alters the chromatin conformation of neighbouring sequences and results in transcriptional activation.


Assuntos
Genes Reguladores , Glicoproteínas/genética , Regiões Promotoras Genéticas , Receptores de Esteroides/fisiologia , Uteroglobina/genética , Animais , Sítios de Ligação , Mapeamento Cromossômico , Desoxirribonuclease I , Endométrio/fisiologia , Estrogênios/farmacologia , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Progesterona/farmacologia , Coelhos , Receptores de Glucocorticoides/metabolismo , Receptores de Progesterona/metabolismo , Distribuição Tecidual
10.
J Steroid Biochem ; 24(1): 19-24, 1986 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-3009974

RESUMO

A first understanding of the molecular events on the DNA level, underlying transcriptional regulation by steroid hormones, has been approached in the last 3 years by means of protein/DNA interaction studies, using purified receptors. This work summarizes our knowledge of how purified glucocorticoid and progestine receptors interact with their cognate regulatory elements associated with polymerase II dependent genes like mouse mammary tumour virus, the genes encoding human metallothionein IIA, chicken lysozyme, human growth hormone and rabbit uteroglobin. The resulting data agree with those of functional test systems, that have been gene-transfer experiments using stable transformants or transient expression. A consensus sequence for the regulatory element of the glucocorticoid receptor could be deduced that, in its three-dimensional representation, gives an impression of the steric mode of interaction. The regulatory elements of the progestine receptor overlap in two analysed cases with those of the glucocorticoid receptor, but are not identical. Furthermore, also a polymerase I transcribed gene encoding ribosomal RNA in the mouse could be shown to contain a glucocorticoid regulatory element that is functional in in vitro transcription experiments. Finally, the latest strategies are the cloning of the glucocorticoid receptor gene and the analysis of receptor-mediated topological effects.


Assuntos
Regulação da Expressão Gênica , Receptores de Glucocorticoides/fisiologia , Receptores de Progesterona/fisiologia , Animais , Sequência de Bases , Sítios de Ligação , Clonagem Molecular , Hormônio do Crescimento/genética , Humanos , Vírus do Tumor Mamário do Camundongo/genética , Metalotioneína/genética , Camundongos , Muramidase/genética , Regiões Promotoras Genéticas , Coelhos , Receptores de Glucocorticoides/genética , Sequências Repetitivas de Ácido Nucleico , Uteroglobina/genética
11.
Nature ; 313(6004): 706-9, 1985.
Artigo em Inglês | MEDLINE | ID: mdl-2983219

RESUMO

The glucocorticoid receptor of rat liver recognizes nucleotide sequences near the promoter of mouse mammary tumour virus (MMTV) required for hormonal induction in gene transfer experiments. Similar nucleotide sequences have been found in the human metallothionein gene IIA and in the chicken lysozyme gene, the later induced also by oestrogen, progesterone and androgens. In microinjection experiments, deletion of only 44 base pairs (bp) of the lysozyme promoter (from -208 to -164) results in coordinated loss of progesterone and glucocorticoid-dependent gene expression. We show here that purified glucocorticoid receptor from rat liver and progesterone receptor from rabbit uterus yield similar or overlapping exonuclease III footprints in the promoter regions of MMTV and chicken lysozyme. Thus, the regulatory elements for different steroid hormones may be similar or at least share structural features.


Assuntos
Vírus do Tumor Mamário do Camundongo/genética , Muramidase/genética , Regiões Promotoras Genéticas , Receptores de Glucocorticoides/genética , Receptores de Progesterona/genética , Receptores de Esteroides/genética , Animais , Sequência de Bases , Exonucleases , Feminino , Regulação da Expressão Gênica , Genes , Fígado/fisiologia , Camundongos , Coelhos , Ratos , Útero/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA